Kivorent News

Friday, November 20, 2026

Health techNews

a2z Radiology AI wins third FDA clearance in a year for abdominal CT triage

a2z Radiology AI received FDA 510(k) clearance for a2z-Omni-Triage, software that flags nine urgent findings on abdomen and pelvis CT, from collapsed lungs to pelvic fractures, for faster radiologist review.

Docket, covering health regulation and AI in care
, 2 min read

26Findings listed across a2z's three cleared CT devices

What to know

  • a2z-Omni-Triage flags nine suspected findings on abdominopelvic CT, including pneumothorax, bowel perforation and aortic aneurysms of 5 cm or more.
  • It is a2z's third clearance in about a year, after a2z-Unified-Triage (seven findings) and a2z-Abdo-Triage (ten).
  • No 510(k) number or performance data had been published with the announcement.

Most of what a2z Radiology AI's new clearance flags isn't in the abdomen at all. A collapsed lung, fluid around the lungs, a fractured sacrum: an abdomen and pelvis CT catches the bottom of the chest and the bones of the pelvis, and the radiologist reading it for appendicitis is still responsible for everything else in the picture. a2z-Omni-Triage, cleared by the FDA through the 510(k) pathway, is built to push those incidental emergencies up the reading list.

Diagnostic Imaging reported the clearance on November 20, from a company release dated November 19. The software flags nine suspected findings: pneumothorax, moderate or large layering pleural effusion, complex pleural collection, bowel perforation, non-sacral pelvic fracture, sacral or coccygeal fracture, soft tissue abscess, moderate or severe hydronephrosis, and aortic aneurysm of 5 cm or larger. It works on CT with or without contrast, according to the company.

Like other triage software, it doesn't diagnose. It reorders a worklist. Michael Moritz, a2z's chief medical information officer, said it "helps bring those studies with suspected findings forward for review."

Three clearances, one scan type

This is a2z's third cleared device, and all three read the same kind of exam. a2z-Unified-Triage (K252366), cleared in November 2025, covers seven findings including small bowel obstruction, acute pancreatitis and free air. a2z-Abdo-Triage followed in September with ten more, from appendicitis to splenic injury, and Diagnostic Imaging reported it also holds a breakthrough device designation.

Add the lists and you get 26 findings (7 + 10 + 9). That overstates the spread a little: hydronephrosis appears on both the first and third lists, and the first device's unruptured abdominal aortic aneurysm overlaps with Omni's large aneurysm. Still, three submissions in about a year means each new batch of findings gets its own FDA review. It's the same 510(k) route GE HealthCare used this week for its feeding tube AI.

What isn't out yet

The release gives no 510(k) number and no accuracy figures. For the first device, the FDA summary showed a 675-case test set from 12 sites, with sensitivity between 88.9% and 98.0% at the balanced setting for the findings reported that way, according to Innolitics' analysis. Whether Omni's harder targets, small pleural collections and subtle sacral fractures among them, hit similar numbers will be in its summary once the FDA posts it. Our guide on reading a 510(k) summary shows where to look. Until then, the clearance tells us the FDA found it substantially equivalent to a predicate, and not much more.

It also arrives nine days before RSNA, the radiology meeting where triage vendors such as Avicenna.AI tend to show their newest tools.

This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.

Sources

FDA and health regulationDigital health and AI in care

Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.